| Long name: |
PANK2 Primary Polyclonal Antibody |
| Also known as: |
PANK2 PAb |
| Category: |
Primary Antibodies |
| Conjugation: |
Unconjugated |
| Target Antigen: |
PANK2 |
| Specificity: |
This is a highly specific antibody against PANK2 |
| Modification(s): |
None |
| Modification site(s): |
Unmodified antibody |
| Clonality: |
Polyclonal antibody |
| Clone number: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Source: |
This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human PANK2 |
| Gene ID number: |
80025 |
| Tested Applications: |
IF(IHC-P), IHC-P, WB |
| Recommended dilutions: |
IF(IHC-P)(1:50-200), IHC-P(1:100-500), WB(1:100-1000) |
| Cross reactivity: |
Mouse, Rat, Human |
| Cross reactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Background of the target antigen: |
All patients have the 'eye of the tiger' sign on brain MRI, Atypical forms have onset in the second decade, Classic forms present with onset in the first decade, Clinical manifestations include progressive muscle spasticity, HARP is a rare syndrome with many clinical similarities to NBIA1, Intermediate forms manifest onset in the first decade with slow progression or onset in the second decade with rapid progression, It is an autosomal recessive neurodegenerative disorder associated with iron accumulation in the brain, It is clinically classified into classic, Patients with early onset tend to also develop pigmentary retinopathy, acanthocytosis, also known as pantothenate kinase-associated neurodegeneration (PKAN) or Hallervorden-Spatz syndrome (HSS), and intellectual deterioration which progresses to severe dementia over several years, and intermediate phenotypes, and pallidal degeneration (HARP), atypical, dysarthria, dystonia, hyperreflexia, loss of independent ambulation within 15 years, maintenance of independent ambulation up to 40 years later, muscle rigidity, primarily in the basal ganglia, rapid progression, retinitis pigmentosa, slow progression, whereas those with later onset tend to also have speech disorders and psychiatric features, Defects in PANK2 are the cause of hypoprebetalipoproteinemia, Defects in PANK2 are the cause of neurodegeneration with brain iron accumulation type 1 (NBIA1) |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA |
| Synonym names: |
HARP, HSS, MGC15053, NBIA1, PANK2, PANK2_HUMAN, PKAN, Pantothenate kinase 2, Pantothenate kinase 2 Hallervorden Spatz syndrome, Pantothenic acid kinase 2, RP23 387C21, hPANK2, 4, C20orf48 |
| Properties: |
C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
PANK2 |
| Short name: |
PANK2 Antibody |
| Technique: |
antibodies against human proteins, antibodies for, Antibody |
| Alternative name: |
PANK2 (Antibody to) |
| Alternative technique: |
antibodies |
| Identity: |
15894 |
| Gene: |
PANK2 |
More about : PANK2 |
| Long gene name: |
pantothenate kinase 2 |
| Synonyms gene: |
C20orf48 NBIA1 |
| Synonyms gene name: |
neurodegeneration with brain iron accumulation 1 (Hallervorden-Spatz syndrome) |
| Synonyms: |
HSS FLJ11729 PKAN HARP |
| Synonyms name: |
Hallervorden-Spatz syndrome |
| Locus: |
20p13 |
| Discovery year: |
2001-06-21 |
| GenBank acession: |
AK021791 |
| Entrez gene record: |
80025 |
| Pubmed identfication: |
8944032 11479594 |
| RefSeq identity: |
NM_024960 |
| Havana BLAST/BLAT: |
OTTHUMG00000031768 |
| Locus Specific Databases: |
LRG_1016 |